VistaGen Therapeutics, Inc. (VTGN)

NASDAQ: VTGN · IEX Real-Time Price · USD
5.28
+0.71 (15.54%)
At close: Mar 28, 2024, 4:00 PM
5.24
-0.04 (-0.76%)
After-hours: Mar 28, 2024, 7:16 PM EDT

Company Description

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.

The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder.

In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders.

Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders.

The company was founded in 1998 and is headquartered in South San Francisco, California.

VistaGen Therapeutics, Inc.
VistaGen Therapeutics logo
Country United States
Founded 1998
Industry Biotechnology
Sector Healthcare
Employees 37
CEO Shawn K. Singh J.D.

Contact Details

Address:
343 Allerton Avenue
South San Francisco, California 94080
United States
Phone 650-577-3600
Website vistagen.com

Stock Details

Ticker Symbol VTGN
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001411685
CUSIP Number 92840H202
ISIN Number US92840H4002
Employer ID 20-5093315
SIC Code 2834

Key Executives

Name Position
Shawn K. Singh J.D. Chief Executive Officer and Director
Reid G. Adler Esq., J.D. Chief Corporate Development Officer and General Counsel
Cynthia Lynn Anderson CPA Chief Financial Officer
Joshua Prince M.B.A. Chief Operating Officer
Mark Adrian McPartland Senior Vice President of Investor Relations
Trisha Fitzmaurice Senior Vice President of Human Resources
Dr. Allen Easley Cato III, M.D., Ph.D. Senior Vice President of Development Operations
Dr. Mark J. Ginski Ph.D. Senior Vice President and Head of Chemistry, Manufacturing and Controls
Mark Flather Senior Vice President of Corporate Strategy and Capital Markets
Dr. Erik Berglund M.D., Ph.D. Senior Vice President of Global Regulatory Affairs and Pharmacovigilance

Latest SEC Filings

Date Type Title
Feb 29, 2024 EFFECT Notice of Effectiveness
Feb 16, 2024 UPLOAD Filing
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 S-3 Registration statement under Securities Act of 1933
Feb 13, 2024 8-K Current Report
Feb 13, 2024 10-Q Quarterly Report